Clinical Trials Browser

Recruiting × orelabrutinib × 30 days × Clear all

NCT07499271 2026-03-30

Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06793189 2026-03-24

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Phase 2 Recruiting

Lymphoma, B-Cell, Marginal Zone